Sir Peter MacCallum Department of Oncology - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/274

Filters

2017 2
2
Reset filters

Settings
Statistics
Citations
Author: Chia, Puey Ling × Author: John, Thomas × End date: 2019 × Start date: 2014 ×

Search Results

Now showing 1 - 2 of 2
  • Item
    Thumbnail Image
    De novo activating epidermal growth factor mutations (EGFR) in small-cell lung cancer
    Thai, A ; Chia, PL ; Russell, PA ; Do, H ; Dobrovic, A ; Mitchell, P ; John, T (WILEY, 2017-09)
    In Australia, mutations in epidermal growth factor mutations (EGFR) occur in 15% of patients diagnosed with non-small-cell lung cancer and are found with higher frequency in female, non-smokers of Asian ethnicity. Activating mutations in the EGFR gene are rarely described in SCLC. We present two cases of de novo EGFR mutations in patients with SCLC detected in tissue and in plasma cell free DNA, both of whom were of Asian ethnicity and never-smokers. These two cases add to the growing body of evidence suggesting that screening for EGFR mutations in SCLC should be considered in patients with specific clinical features.
  • Item
    Thumbnail Image
    Treatment of ALK-rearranged non- small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context
    Itchins, M ; Chia, PL ; Hayes, SA ; Howell, VM ; Gill, AJ ; Cooper, WA ; John, T ; Mitchell, P ; Millward, M ; Clarke, SJ ; Solomon, B ; Pavlakis, N (WILEY, 2017-08)
    Since the identification of anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) in 2005, the treatment of ALK-rearranged NSCLC (ALK+ NSCLC) has evolved at a rapid pace. This molecularly distinct subset of NSCLC has uniquely important biology, clinicopathologic features and mechanisms of drug resistance which impact on the choice of treatment for a patient with this disease. There are multiple ALK tyrosine kinase inhibitors now available in clinical practice with efficacy data continuing to emerge and guide the optimal treatment algorithm. A detailed search of medical databases and clinical trial registries was conducted to capture all relevant articles on this topic enabling an updated detailed overview of the landscape of management of ALK-rearranged NSCLC.